Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
This Bitcoin-first microcap is using its balance sheet to accumulate BTC (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Vaxxinity Inc (EM) VAXX

Healthcare Biotechnology
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer’s disease; UB-312, which is in phase 1 clinical... see more

Recent & Breaking News (EXPM:VAXX)

Vaxxinity UB-312 Parkinson's Trial Results Published in Nature Medicine

GlobeNewswire June 20, 2024

Vaxxinity Issues Shareholder Letter

GlobeNewswire April 19, 2024

Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock

GlobeNewswire April 19, 2024

Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting

GlobeNewswire March 28, 2024

Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates

GlobeNewswire March 27, 2024

Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson's Disease at AD/PD(TM) 2024

GlobeNewswire March 7, 2024

Vaxxinity's Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published

GlobeNewswire February 15, 2024

Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024

GlobeNewswire February 13, 2024

Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Florida

GlobeNewswire January 30, 2024

Vaxxinity Announces Collaboration on Space Medicine Research with University of Central Florida

GlobeNewswire January 18, 2024

Vaxxinity to Present at the 2024 J.P. Morgan Healthcare Conference

GlobeNewswire January 3, 2024

Vaxxinity to Present at Upcoming November Medical and Investor Conferences

GlobeNewswire November 13, 2023

Vaxxinity Reports Third Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire November 8, 2023

Vaxxinity to Present at Upcoming Investor Conferences in September

GlobeNewswire August 29, 2023

Vaxxinity Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer's Disease

GlobeNewswire August 10, 2023

Vaxxinity Reports Second Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire August 9, 2023

Vaxxinity Appoints Peter Powchik, M.D., to Executive Vice President, Global Scientific Director

GlobeNewswire July 27, 2023

Vaxxinity Demonstrates Target Engagement of Toxic Alpha-Synuclein in Parkinson's Patients

GlobeNewswire July 17, 2023

Vaxxinity Announces UB-312 Successfully Met Primary Objectives of Phase 1 Clinical Trial in Parkinson's Disease

GlobeNewswire June 22, 2023

Vaxxinity Reports First Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire May 9, 2023

Podcasts